Efficacy of combined immunotherapy and chemotherapy in recurrent non‑small cell lung cancer during durvalumab maintenance therapy: A case report

Maze,Yuki; Mitsumura,Takahiro; Nakahama,Hiroshi; Kato,Tatsuya; Takahashi,Yui; Nei,Yuichiro; Hanada,Shigeo; Miyamoto,Atsushi; Uruga,Hironori; Fujii,Takeshi; Tamaoka,Meiyo

doi:10.3892/ol.2025.15288

Efficacy of combined immunotherapy and chemotherapy in recurrent non‑small cell lung cancer during durvalumab maintenance therapy: A case report

Authors:
- Yuki Maze
- Takahiro Mitsumura
- Hiroshi Nakahama
- Tatsuya Kato
- Yui Takahashi
- Yuichiro Nei
- Shigeo Hanada
- Atsushi Miyamoto
- Hironori Uruga
- Takeshi Fujii
- Meiyo Tamaoka
View Affiliations

Affiliations: Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105‑8470, Japan, Department of Pathology, Toranomon Hospital, Tokyo 105‑8470, Japan
Published online on: September 22, 2025 https://doi.org/10.3892/ol.2025.15288
Article Number: 542
Copyright: © Maze et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Concurrent chemoradiotherapy (CCRT) followed by durvalumab consolidation is the standard treatment for patients with locally advanced non‑small cell lung cancer (NSCLC) with a good performance status. However, there is currently no consensus on the management of recurrence after CCRT and durvalumab consolidation therapy. The present study describes the case of a 52‑year‑old male former smoker with stage IIIB NSCLC who experienced recurrence in the right hilar, mediastinal and bilateral supraclavicular lymph nodes after an initial response to CCRT and durvalumab. A treatment regimen involving combined durvalumab, tremelimumab, cisplatin and pemetrexed achieved stable disease and was continued as maintenance therapy. However, the patient later developed brain and bone metastases, indicating progressive disease. This case highlights the challenges of managing recurrent NSCLC after CCRT and durvalumab consolidation therapy. Combining immunotherapy and chemotherapy may offer a viable approach, underscoring the need for further research and standardized protocols.

View Figures

View References

1	Pritchard RS and Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A mata-anaysis. Ann Intern Med. 125:723–729. 1996. View Article : Google Scholar : PubMed/NCBI
2	Marino P, Preatoni A and Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 76:593–601. 1995. View Article : Google Scholar : PubMed/NCBI
3	Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
4	Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 379:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
5	Naito Y, Kubota K, Nihei K, Fujii T, Yoh K, Niho S, Goto K, Ohmatsu H, Saijo N and Nishiwaki Y: Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III Non-small cell lung cancer. J Thorac Oncol. 3:617–622. 2008. View Article : Google Scholar : PubMed/NCBI
6	Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, et al: Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. J Clin Oncol. 41:1213–1227. 2023. View Article : Google Scholar : PubMed/NCBI
7	Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, et al: Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 28:3739–3745. 2010. View Article : Google Scholar : PubMed/NCBI
8	Sasaki T, Seto T, Yamanaka T, Kunitake N, Shimizu J, Kodaira T, Nishio M, Kozuka T, Takahashi T, Harada H, et al: A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Br J Cancer. 119:675–682. 2018. View Article : Google Scholar : PubMed/NCBI
9	Shukuya T, Takahashi T, Harada H, Akamatsu H, Sakaguchi C, Imai H, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, et al: Comparison of vinorelbine plus cisplatin and s-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III Non-small Cell lung cancer. Anticancer Res. 32:675–680. 2012.PubMed/NCBI
10	Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
11	Rogers SJ, Lomax N, Alonso S, Lazeroms T and Riesterer O: Radiosurgery for five to fifteen brain metastases: A single centre experience and a review of the literature. Front Oncol. 12:8665422022. View Article : Google Scholar : PubMed/NCBI
12	Dewan MC, Rattani A, Fieggen G, Arraez MA, Servadei F, Boop FA, Johnson WD, Warf BC and Park KB: Global neurosurgery: The current capacity and deficit in the provision of essential neurosurgical care. Executive summary of the global neurosurgery initiative at the program in global surgery and social change. J Neurosurg. 130:1055–1064. 2018. View Article : Google Scholar : PubMed/NCBI
13	Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, et al: Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 40:1301–1311. 2022. View Article : Google Scholar : PubMed/NCBI
14	Hasegawa T, Ariyasu R, Tanaka H, Saito R, Kawashima Y, Horiike A, Sakatani T, Tozuka T, Shiihara J, Saiki M, et al: Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: A multicenter retrospective analysis (TOPGAN 2021-02). Cancer Chemother Pharmacol. 92:29–37. 2023. View Article : Google Scholar : PubMed/NCBI
15	Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, et al: Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort study. Lancet Oncol. 22:836–847. 2021. View Article : Google Scholar : PubMed/NCBI
16	Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, et al: Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 23:279–291. 2022. View Article : Google Scholar : PubMed/NCBI
17	Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, et al: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. Lancet Oncol. 22:198–211. 2021. View Article : Google Scholar : PubMed/NCBI
18	Lau B, No HJ, Wu YF, Ko RB, Devine M, Das M, Neal JW, Wakelee HA, Ramchandran KJ, Wakelee HA, et al: Pulmonary hemorrhage in patients treated with thoracic stereotactic ablative radiotherapy and anti-angiogenic agents. Int J Radiat Oncol Biol Phys. 111:e4232021. View Article : Google Scholar